Related Experiment Video
Updated: May 25, 2026
Murine Model of Epicutaneously-Induced Immunomodulation
Published on: June 24, 2025
Interspecies comparison of human and murine scleroderma reveals IL-13 and CCL2 as disease subset-specific targets
Matthew B Greenblatt1, Jennifer L Sargent2, Giuseppina Farina3
1Department of Immunology and Infectious Diseases, Harvard School of Public Health, Boston, Massachusetts.
Abstract:
Development of personalized treatment regimens is hampered by lack of insight into how individual animal models reflect subsets of human disease, and autoimmune and inflammatory conditions have proven resistant to such efforts. Scleroderma is a lethal autoimmune disease characterized by fibrosis, with no effective therapy. Comparative gene expression profiling showed that murine sclerodermatous graft-versus-host disease (sclGVHD) approximates an inflammatory subset of scleroderma estimated at 17% to 36% of patients analyzed with diffuse, 28% with limited, and 100% with localized scleroderma. Both sclGVHD and the inflammatory subset demonstrated IL-13 cytokine pathway activation. Host dermal myeloid cells and graft T cells were identified as sources of IL-13 in the model, and genetic deficiency of either IL-13 or IL-4Rα, an IL-13 signal transducer, protected the host from disease. To identify therapeutic targets, we explored the intersection of genes coordinately up-regulated in sclGVHD, the human inflammatory subset, and IL-13-treated fibroblasts; we identified chemokine CCL2 as a potential target. Treatment with anti-CCL2 antibodies prevented sclGVHD. Last, we showed that IL-13 pathway activation in scleroderma patients correlated with clinical skin scores, a marker of disease severity. Thus, an inflammatory subset of scleroderma is driven by IL-13 and may benefit from IL-13 or CCL2 blockade. This approach serves as a model for personalized translational medicine, in which well-characterized animal models are matched to molecularly stratified patient subsets.
Insights
A novel mouse model of scleroderma (sclGVHD) mimics a human inflammatory subset, revealing Interleukin-13 (IL-13) as a key driver. Blocking IL-13 or chemokine CCL2 shows therapeutic potential for this scleroderma subset.
Area of Science:
- Immunology
- Translational Medicine
- Dermatology
Background:
- Personalized treatment for autoimmune diseases like scleroderma is challenging due to limited understanding of animal model relevance to human disease subsets.
- Scleroderma, a fibrotic autoimmune disease, lacks effective therapies, particularly for inflammatory subsets.
- Murine sclerodermatous graft-versus-host disease (sclGVHD) serves as a relevant model for specific human scleroderma inflammatory subsets.
Purpose of the Study:
- To investigate the molecular mechanisms driving an inflammatory subset of scleroderma using a comparative approach with a murine model.
- To identify potential therapeutic targets by analyzing gene expression profiles in sclGVHD, human scleroderma subsets, and IL-13-stimulated cells.
- To validate the role of Interleukin-13 (IL-13) and chemokine CCL2 as therapeutic targets in scleroderma.
Main Methods:
- Comparative gene expression profiling of murine sclGVHD and human scleroderma patient subsets.
- Identification of key cytokine pathways, specifically IL-13 signaling, involved in disease pathogenesis.
- Analysis of IL-13 production sources (myeloid and T cells) and genetic manipulation (IL-13 or IL-4Rα deficiency).
- Exploration of coordinately up-regulated genes to identify therapeutic targets, focusing on chemokine CCL2.
- In vivo validation of anti-CCL2 antibody treatment in the sclGVHD model.
- Correlation analysis of IL-13 pathway activation with clinical skin scores in scleroderma patients.
Main Results:
- Murine sclGVHD closely approximates specific inflammatory subsets of human scleroderma (17-36% diffuse, 28% limited, 100% localized).
- Both sclGVHD and the human inflammatory subset exhibit significant Interleukin-13 (IL-13) pathway activation.
- IL-13 is produced by host dermal myeloid cells and graft T cells; genetic deficiency of IL-13 or IL-4Rα confers protection.
- Chemokine CCL2 was identified as a key target, and anti-CCL2 antibody treatment effectively prevented sclGVHD.
- IL-13 pathway activation in patients significantly correlates with disease severity (clinical skin scores).
Conclusions:
- An inflammatory subset of scleroderma is critically driven by the IL-13 pathway.
- Therapeutic strategies targeting IL-13 or CCL2 blockade show promise for this scleroderma patient subset.
- This study provides a model for personalized translational medicine by matching animal models to molecularly defined patient subsets.
